These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9552174)

  • 21. The kinetic behaviour of [3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms.
    Deep P; Kuwabara H; Gjedde A; Cumming P
    J Neurosci Methods; 1997 Dec; 78(1-2):157-68. PubMed ID: 9497012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine.
    Firnau G; Garnett ES; Chirakal R; Sood S; Nahmias C; Schrobilgen G
    Int J Rad Appl Instrum A; 1986; 37(8):669-75. PubMed ID: 3021668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of metabolites from monkey striatum during PET with FDOPA.
    Cumming P; Munk OL; Doudet D
    Synapse; 2001 Sep; 41(3):212-8. PubMed ID: 11391782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
    Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
    Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat.
    Reith J; Dyve S; Kuwabara H; Guttman M; Diksic M; Gjedde A
    J Cereb Blood Flow Metab; 1990 Sep; 10(5):707-19. PubMed ID: 2117017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
    Borri Voltattorni C; Bertoldi M; Bianconi S; Deng WP; Wong K; Kim I; Herbert B; Kirk KL
    Biochem Biophys Res Commun; 2002 Jul; 295(1):107-11. PubMed ID: 12083775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
    Nagasawa H; Tanji H; Itoh M; Itoyama Y
    Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
    Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
    Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
    Holden JE; Doudet D; Endres CJ; Chan GL; Morrison KS; Vingerhoets FJ; Snow BJ; Pate BD; Sossi V; Buckley KR; Ruth TJ
    J Nucl Med; 1997 Oct; 38(10):1568-74. PubMed ID: 9379194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model.
    Hefti F; Melamed E; Wurtman RJ
    J Neural Transm Suppl; 1980; (16):95-101. PubMed ID: 6776238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [3H]DOPA formed from [3H]tyrosine in living rat brain is not committed to dopamine synthesis.
    Cumming P; Ase A; Kuwabara H; Gjedde A
    J Cereb Blood Flow Metab; 1998 May; 18(5):491-9. PubMed ID: 9591841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.
    Hartvig P; Agren H; Reibring L; Tedroff J; Bjurling P; Kihlberg T; Långström B
    J Neural Transm Gen Sect; 1991; 86(1):25-41. PubMed ID: 1751027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder.
    Ernst M; Zametkin AJ; Matochik JA; Pascualvaca D; Jons PH; Cohen RM
    Am J Psychiatry; 1999 Aug; 156(8):1209-15. PubMed ID: 10450262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
    Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
    J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
    Opacka-Juffry J; Brooks DJ
    Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
    Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and alpha-substituted catecholamines.
    Gordonsmith RH; Raxworthy MJ; Gulliver PA
    Biochem Pharmacol; 1982 Feb; 31(3):433-7. PubMed ID: 6803810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.